Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | QDPR | P09417 | 3/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | DBH | P09172 | 1/20 | 0.34 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21471548 | 0.83 | HDAC4 (0.74) | HDAC4HDAC2HDAC8ESR2KMO | |
| SCHEMBL21471547 | 0.81 | HDAC4 (0.72) | HDAC4HDAC2HDAC8KMOQDPR | |
| SCHEMBL23250714 | 0.80 | HDAC4 (0.45) | HDAC4HDAC2HDAC8ESR2ESR1 | |
| SCHEMBL23258718 | 0.80 | HDAC4 (0.45) | HDAC4HDAC2HDAC8ESR2ESR1 | |
| SCHEMBL23258566 | 0.79 | QDPR (0.62) | HDAC4HDAC2HDAC8KMOQDPR | |
| SCHEMBL23258680 | 0.79 | HDAC4 (0.54) | HDAC4HDAC2HDAC8KMOQDPR | |
| SCHEMBL23250721 | 0.75 | HDAC4 (0.49) | HDAC4HDAC2HDAC8KMOQDPR | |
| SCHEMBL23250778 | 0.73 | HDAC4 (0.47) | HDAC4HDAC2HDAC8KMOQDPR | |
| SCHEMBL27304673 | 0.73 | QDPR (0.69) | HDAC4HDAC2HDAC8QDPRDRD2 | |
| SCHEMBL27308722 | 0.72 | HDAC4 (0.41) | HDAC4HDAC2HDAC8ESR2QDPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073131-A2 | METHOD OF TREATING NEURODEGENERATIVE DISEASES | THE BOARD OF TRUSTEES OF THE UNIVESITY OF ILLINOIS (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20230406803-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | Kinesid Therapeutics, Inc (US) | 2023-12-21 | — | — | US | disclosed |
| EP-4045477-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | Ambys Medicines, Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2021076938-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | Ambys Medicines, Inc. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021076938-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | Ambys Medicines, Inc. (US) | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406803-A1 | TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS | TXNRD2, TFRC, SDHB | HDAC4 2346/4885HDAC2 2245/4885HDAC8 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.